- You are
- Patients and relatives
- To be cared for and supported
- Become an expert patient
- Research
Niche, Cancer, and Radiation in Hematopoiesis
Françoise Pflumio
Team Leader
Team's research themes
The team explores interactions between the bone marrow niches and pathological cells in hematopoiesis, develops innovative strategies against acute radiation syndromes, and designs preclinical approaches to improve leukemia treatments and post-transplant regeneration, integrating humanized models, cellular therapies, and clinical collaborations.
Studied Pathologies
Acute lymphoblastic leukemias (B/T-ALL)
Acute myeloblastic leukemias (AMKL)
Pre-leukemic diseases
Myeloproliferative syndromes (myelofibrosis)
Hematopoietic regeneration after genotoxic stress (irradiation, chemotherapy)
Hematipoiesis and Gastro-Intestinal acute radiation syndromes (H-ARS/GI-ARS)
Research areas
Development of innovative treatments (chemical molecules, Mesenchymal Stromal/Stem cells “Muse” , extracellular vesicles) to protect hematopoietic and intestinal tissues from the lethal effects of acute irradiation, using murine and humanized models, in partnership with European and national programs.
Mechanistic study of the impact of leukemic (B/T-ALL ; AMKL) and myeloproliferative cells on the bone marrow niche, using cellular, murine, and humanized ossicle models, to identify signals promoting therapeutic resistance, fibrosis, and malignant transformation, with a translational focus on PPARγ and pediatric leukemogenesis modeling.
Targeting E-selectin interaction to restore leukemia chemosensitivity and development of T progenitor cell therapy (ProTcells) to accelerate thymic and immune regeneration after hematopoietic stem cells transplantation, particularly in elderly patients.
Featured research projects
Molecules and Muse Cells Against ARS
Testing radioprotective molecules and stem cells in murine models of acute irradiation.
PPARγ in Myelofibrosis
Validation of PPARγ activation as an anti-fibrosis strategy in preclinical myelofibrosis models.
E-selectin Antagonists in Leukemia
Evaluation of molecules to block leukemia-microenvironment interaction and restore chemosensitivity.
Team members
Pflumio FrançoiseDR InsermCalvo JulienResearcher CEAHaddad RimaMCU UPSaclayRenou LaurentEngineer/Researcher CEAGault NathalieResearcher CEAMoreno StéphanieResearcher CEALewandowski DanielResearcher CEAFerri FedericaResearcher CEAProst StéphaneDR CEARoche-Naude JeannePhD Student CEABenmeziane KeltoumaCDD CEAGilain FlorianStudy Engineer INSERMTaibi ThilelliPhD Student CEAHouques ChloéPost-doc CEABoubacar TiganaResearch Technician CEATuil JohannaMaster 2 CEARousselot PhilippePU-PHBardet ValériePU-PHClauser SylvainMCU-PHLambert JulietteMD, PhDScientific Publications
High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
Julien Calvo & al, Leukemia, 2025Lire la publication
Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia
Verónica Alonso-Pérez & al, Molecular Cancer, 2024Lire la publication
PPARγ agonists promote the resolution of myelofibrosis in preclinical models
Lambert J & al, J Clin Invest, 2021Lire la publicationJob Offers
Engineer/Technician
Planned recruitment to support transversal projects (radiobiology and leukemogenesis).
Télécharger le PDF
Researcher
Active application for an Inserm/CEA position to strengthen the team and energize scientific axes.
Télécharger le PDFIndustrial partners
Clinical partners
Funding
- Become an expert patient
- To be cared for and supported
- Patients and relatives
